Tesaro (TSRO) PT Lowered to $76 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
February 27, 2018 4:05 PM ESTZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S.2017 ZEJULA® net sales totaled $109 million during first nine months of commercial launchFocused clinical development program for niraparib in ovarian cancer is advancing in first-line and platinum-resistant settingsMultiple immuno-oncology clinical studies to read out in 2018Enrollment of registration trial of TSR-042 (anti-PD-1 mAb) to complete by YE 2018
WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company,... More
